Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach

详细信息    查看全文

• 作者：Tiziana Comito ; Luca Cozzi ; Elena Clerici ; Maria Concetta Campisi…
• 关键词：Liver ; Lung ; Colorectal oligometastases ; RapidArc ; Stereotactic ablative radiotherapy
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：737 KB
• 参考文献：1. Hellman, S, Weichselbaum, RR (1995) Oligometastases. J Clin Oncol 13: pp. 8-10
  2. Milano, M, Katz, A, Muhs, A, Philip, A, Buchholz, D, Schell, M, Okunieff, P (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112: pp. 650-658 CrossRef
  3. Milano, M, Philip, A, Okunieff, P (2009) Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Rad Onc Biol Phys 73: pp. 832-837 CrossRef
  4. Weichselbaum, RR, Hellman, S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8: pp. 378-382
  5. Yoon, SS, Tanabe, KK (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4: pp. 197-208
  6. Scheele, J, Stangl, R, Altendorf-Hofmann, A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77: pp. 1241-1246 CrossRef
  7. Fong, Y, Fortner, J, Sun, RL, Brennan, M, Blumgart, L (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: pp. 309-318 CrossRef
  8. Elias, D, Liberale, G, Vernerey, D, Pocard, M, Manganas, D, Ducreux, M, Boige, V, Malka, D, Pignon, J, Lasser, P (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12: pp. 900-909 CrossRef
  9. Inoue, M, Ohta, M, Iuchi, K, Matsumura, A, Ideguchi, K, Yasumitsu, T, Nakagawa, K, Fukuhara, K, Maeda, H, Takeda, S, Minami, M, Ohno, Y, Matsuda, H (2004) Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78: pp. 238-244 CrossRef
  10. Pfannschmidt, J, Dienemann, H, Hoffmann, H (2007) Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 84: pp. 324-338 CrossRef
  11. Kanemitsu, Y, Kato, T, Hirai, T, Yasui, K (2004) Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91: pp. 112-120 CrossRef
  12. Gillams, AR, Lees, WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19: pp. 1206-1213 CrossRef
  13. Siperstein, A, Berber, E, Ballem, N, Pariku, R (2007) Survival after radiofrequency ablation of colorectal liver metastases. 10-year experience. Ann Surg 246: pp. 559-567 CrossRef
  14. Chua, TC, Thornbury, K, Saxena, A, Liauw, W, Glenn, D, Zhao, J, Morris, D (2010) Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer 116: pp. 2106-2114 CrossRef
  15. Alongi, F, Arcangeli, S, Filippi, AR, Ricardi, U, Scorsetti, M (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17: pp. 1100-1107 CrossRef
  16. Rusthoven, KE, Kavanagh, BD, Cardenes, H, Stieber, V, Burri, S, Feigenberg, S, Chidel, M, Pugh, T, Franklin, W, Kane, M, Gaspar, L, Scheffer, T (2009) Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27: pp. 1572-1578 CrossRef
  17. Lee, M, Kim, J, Dinniwell, R, Brierl
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer. Methods 82 patients with 1- inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity. Results Median follow-up was 24?months (range 3-7). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ?0 Gy (n--8) and those irradiated with p--em class="a-plus-plus">0.04). Median OS was 32?months. Actuarial OS rate at 1, 2 and 3?yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV--?cm (p--em class="a-plus-plus">0.02). Median PFS was 14?months, with a PFS rate of 56% at 1?yr and 40% at 2-3?yrs, without correlation with the site and prescription dose (p--em class="a-plus-plus">0.48 and p--em class="a-plus-plus">0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity. Conclusions SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.